Enzalutamide Treatment in COVID-19

Summary

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

Conditions

• COVID-19
• Corona Virus Infection

Interventions

DRUG

Enzalutamide Pill

The once daily dose will be given only during hospitalization and stop if starting invasive mechanical ventilation or at discharge from hospital

Sponsors & Collaborators

• Umeå University

  collaborator OTHER

• Sahlgrenska University Hospital

  collaborator OTHER

• University Hospital, Umeå

  collaborator OTHER

• Uppsala University Hospital

  collaborator OTHER

• Skane University Hospital

  collaborator OTHER

• Jonkoping County Hospital

  collaborator OTHER

• Sundsvall Hospital

  collaborator OTHER

• Helsingborgs Hospital

  collaborator OTHER

• Göteborg University

  collaborator OTHER

• Astellas Pharma Europe Ltd.

  collaborator INDUSTRY

• Norrlands University Hospital

  collaborator OTHER

• Andreas Josefsson

  lead OTHER_GOV

Principal Investigators

• Andreas Josefsson, MdPhD · Norrlands University Hospital, Region Västerbotten

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-15

Primary Completion

2021-03-24

Completion

2021-05-29

Countries

• Sweden

Study Locations